Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 1/2 1

Status

Active not recruiting 2Recruiting 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 2Thoracic 1Genitourinary 1Gastrointestinal 1Dermatologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 56Squamous Cell Carcinoma of Head and Neck 31Lung Neoplasms 17Head and Neck Neoplasms 17Urinary Bladder Neoplasms 16Oropharyngeal Neoplasms 14Parkinson Disease 4, Autosomal Dominant Lewy Body 11Nasopharyngeal Carcinoma 11Carcinoma 10Small Cell Lung Carcinoma 9Carcinoma, Squamous Cell 9Uterine Cervical Neoplasms 8Pancreatic Neoplasms 8Ovarian Neoplasms 8Carcinoma, Transitional Cell 8Neoplasm Metastasis 7Mouth Neoplasms 7Breast Neoplasms 7Triple Negative Breast Neoplasms 6Recurrence 6Neoplasms 6Melanoma 6Gallbladder Neoplasms 6Esophageal Squamous Cell Carcinoma 6Esophageal Neoplasms 6Colorectal Neoplasms 6Biliary Tract Neoplasms 6Mesothelioma, Malignant 5Medulloblastoma 5Laryngeal Neoplasms 5

Interventions

Cisplatin 2pembrolizumab 1durvalumab 1anlotinib 1Taxes 1Radiotherapy, Intensity-Modulated 1Pemetrexed 1Paclitaxel 1Nimorazole 1Immunotherapy 1Cell Count 1CP protocol 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Neoplasms, Glandular and Epithelial × Cisplatin × Clear all
NCT04124198 2025-12-31

QoLATI

Rigshospitalet, Denmark

Phase NA Active not recruiting
138 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Carcinoma, Squamous Cell, DNA Virus Infections, Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Oropharyngeal Neoplasms, Otorhinolaryngologic Diseases, Otorhinolaryngologic Neoplasms, Pharyngeal Diseases, Tumor Virus Infections, Virus Diseases, Neoplasms, Squamous Cell, Papillomavirus Infections

NCT04198766 2025-12-18

Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

Inhibrx Biosciences, Inc

Phase 1/2 Active not recruiting
296 enrolled
DermatologicGastrointestinalGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Head and Neck Neoplasms, Hypopharyngeal Neoplasms, Lung Neoplasms, Melanoma, Mouth Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Oropharyngeal Neoplasms, Stomach Neoplasms, Neoplasms, Squamous Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡